SkinBioTherapeutics PLC
SBTX
Company Profile
Business description
SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
Contact
Bath Lane
The Core, Newcastle Helix
Newcastle upon TyneNE4 5TF
GBRT: +44 1914957325
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
41
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks
Higher interest rates boost earnings for ASX real estate platform
Interest rates are driving a spike in property listings.
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,868.30 | 4.70 | -0.05% |
| CAC 40 | 7,979.92 | 76.46 | -0.95% |
| DAX 40 | 23,954.93 | 395.35 | -1.62% |
| Dow JONES (US) | 49,760.56 | 56.09 | 0.11% |
| FTSE 100 | 10,265.32 | 4.11 | -0.04% |
| HKSE | 26,347.91 | 58.93 | -0.22% |
| NASDAQ | 26,088.20 | 185.92 | -0.71% |
| Nikkei 225 | 62,520.11 | 222.46 | -0.35% |
| NZX 50 Index | 13,043.10 | 37.23 | -0.28% |
| S&P 500 | 7,400.96 | 11.88 | -0.16% |
| S&P/ASX 200 | 8,624.50 | 6.50 | -0.08% |
| SSE Composite Index | 4,214.49 | 10.53 | -0.25% |